$AZN (AstraZeneca PLC)

$AZN {{ '2015-10-22T17:11:09+0000' | timeago}} • Announcement

$LLY and $AZN announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for solid tumor treatment. By this agreement, $LLY will lead the execution of the studies and both companies will evaluate the safety and efficacy of a range of additional combinations across the portfolios.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$ILMN {{ '2018-01-16T12:42:12+0000' | timeago}} • Announcement

Luna DNA, the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community, appointed Dawn Barry as president. Previously, Barry served as the VP of Applied Genomics at $ILMN.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$TMO {{ '2018-01-09T12:43:22+0000' | timeago}} • Announcement

$TMO, a leading medical technology company, has signed an agreement with life sciences firm $ILMN, under which Thermo Fisher will provide Illumina with Ion AmpliSeq technology. The tie-up will help Illumina effectively sell Ion AmpliSeq technology to researchers engaged in scientific studies on its next-generation sequencing (NGS) platforms.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$BMY {{ '2017-12-18T12:54:53+0000' | timeago}} • Announcement

$BMY announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of Yervoy for pediatric patients 12 years of age and older who have unresectable or metastatic melanoma. The CHMP recommendation will now be reviewed by the European Commission.

$REGN {{ '2017-12-18T12:38:12+0000' | timeago}} • Announcement

$REGN and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. $REGN and ISA will jointly conduct trials of treatment in cervical cancer and head-and-neck cancer.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$ILMN {{ '2017-12-11T15:09:10+0000' | timeago}} • Announcement

$ILMN said Aimee Hoyt will head its human resources team. Hoyt will join as SVP and Chief People Officer (CPO), starting Jan. 8, 2018, and will be responsible for leading all aspects of the company’s HR strategies, reporting to CEO Francis deSouza.

$MDT {{ '2017-12-08T21:21:14+0000' | timeago}} • Announcement

$MDT BoD approved 3Q18 cash dividend of $0.46 per ordinary share, representing a 7% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2017.

$DIS {{ '2017-12-08T11:53:58+0000' | timeago}} • Announcement

$DIS' BoD elected two new directors: Safra Catz, CEO of global-technology leader $ORCL, and Francis deSouza, President and CEO of biotechnology firm $ILMN. The elections of Catz and deSouza are effective Feb. 1, 2018.

$BMY {{ '2017-12-07T23:37:10+0000' | timeago}} • Announcement

$BMY declared a 2.6% hike in the quarterly dividend, beginning in 1Q18. The increase will result in a quarterly dividend of $0.40 per share. The next quarterly dividend will be payable on Feb. 1, 2018, to stockholders of record at the close of business on Jan. 5, 2018.

$BMY {{ '2017-12-07T18:05:15+0000' | timeago}} • Announcement

$BMY announced the FDA lifted partial clinical holds placed on CA209 -039 and CA204142, the phase 1 and 2 clinical trials investigating Opdivo (nivolumab)-based combinations in patients with relapsed or refractory multiple myeloma, respectively.

$VAR {{ '2017-12-07T15:05:38+0000' | timeago}} • Announcement

Medical devices maker $VAR said it received ANVISA registration for its cancer treatment device Halcyon in Brazil. The registration allows the company to market the new system in the Latin American country. Halcyon is designed to simplify operations and save time without compromising on quality.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
PBYI (Puma Biotechnology, Inc.)
Thursday, November 9 2017 - 9:30pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, November 7 2017 - 9:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 4:30pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 12:30pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, November 2 2017 - 12:30pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm

AlphaGraphics you may like